학술논문
Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer.
Document Type
Article
Author
Source
Subject
*HER2 positive breast cancer
*METASTATIC breast cancer
*TRASTUZUMAB
*MONONUCLEAR leukocytes
*CELL-free DNA
*
*
*
*
Language
ISSN
1476-4598
Abstract
HER2 amplification was assessed in the last tumor tissue available before T-DM1 administration vs a tumor re-biopsy collected at disease progression from the same patients (n = 4). HER2 counterselection in blood was confirmed in 3/4 matched (from the same patient) tumor re-biopsies at progression, the only exception being a HER2-positive brain metastasis developing against a HER2-neutral blood background (pt#5; Fig. Keywords: HER2+ breast cancer; T-DM1; Liquid biopsy; Circulating tumor DNA; Pharmacological resistance EN HER2+ breast cancer T-DM1 Liquid biopsy Circulating tumor DNA Pharmacological resistance 1 6 6 11/30/21 20211129 NES 211129 Matteo Allegretti and Alessandra Fabi contributed equally to this work. [Extracted from the article]